Augmented interferon regulatory factor 7 axis in whole tumor cell vaccines prevents tumor recurrence by inducing interferon gamma-secreting B cells

References

• Sheikhi A, Jafarzadeh A, Kokhaei P, Hojjat-Farsangi M. Whole tumor cell vaccine adjuvants: comparing IL-12 to IL-2 and IL-15. Iran J Immunol. 2016;13:148–11.
   PubMed Web of Science ®Google Scholar
• Wang F, Gao J, Wang S, Jiang J, Ye Y, Ou J, Liu S, Peng F, Tu Y. Near infrared light activation of an injectable whole-cell cancer vaccine for cancer immunoprophylaxis and immunotherapy. Biomater Sci. 2021;9:3945–3953. doi:10.1039/d1bm00542a.
   PubMed Web of Science ®Google Scholar
• Aikins ME, Xu C, Moon JJ. Engineered nanoparticles for cancer vaccination and immunotherapy. Acc Chem Res. 2020;53:2094–2105. doi:10.1021/acs.accounts.0c00456.
   PubMed Web of Science ®Google Scholar
• Lollini PL, Cavallo F, Nanni P, Quaglino E. The promise of preventive cancer vaccines. Vaccines (Basel). 2015;3:467–489. doi:10.3390/vaccines3020467.
   PubMed Web of Science ®Google Scholar
• Keenan BP, Jaffee EM. Whole cell vaccines - Past progress and future strategies. Semin Oncol. 2012;39:276–286. doi:10.1053/j.seminoncol.2012.02.007.
   PubMed Web of Science ®Google Scholar
• Liu J, Fu M, Wang M, Wan D, Wei Y, Wei X. Cancer vaccines as promising immuno-therapeutics: platforms and current progress. J Hematol Oncol. 2022 15; 15: doi:10.1186/s13045-022-01247-x.
   Web of Science ®Google Scholar
• Huber ML, Haynes L, Parker C, Iversen P. Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst. 2012;104:273–279. doi:10.1093/jnci/djr514.
   PubMed Web of Science ®Google Scholar
• Joshi VB, Geary SM, Gross BP, Wongrakpanich A, Norian LA, Salem AK. Tumor lysate-loaded biodegradable microparticles as cancer vaccines. Expert Rev Vaccines. 2014;13:9–15. doi:10.1586/14760584.2014.851606.
   PubMed Web of Science ®Google Scholar
• Al-Tameemi M, Chaplain M, D’onofrio A. Evasion of tumours from the control of the immune system: consequences of brief encounters. 2012; 7: 31. http://www.biology-direct.com/content/7/1/31.
   Google Scholar
• Au KM, Balhorn R, Balhorn MC, Park SI, Wang AZ. High-performance concurrent chemo-immuno-radiotherapy for the treatment of hematologic cancer through selective high-affinity ligand antibody mimic-functionalized doxorubicin-encapsulated nanoparticles. ACS Cent Sci. 2019;5:122–144. doi:10.1021/acscentsci.8b00746.
   PubMed Web of Science ®Google Scholar
• Abe H, Wada H, Baghdadi M, Nakanishi S, Usui Y, Tsuchikawa T, Shichinohe T, Hirano S, Seino KI. Identification of a highly immunogenic mouse breast cancer sub cell line, 4t1-s. 2016;29:58–66. 10.1007/s13577-015-0127-1. Hum Cell.
   Google Scholar
• Soiffer RJ, Kooshesh KA, Ho V. Whole tumor cell vaccines engineered to secrete GM‐CSF (GVAX). ImmunoMedicine. 2021;1. doi:10.1002/imed.1025.
   PubMedGoogle Scholar
• Hege KM, Jooss K, Pardoll D. GM-CSF gene-modifed cancer cell immunotherapies: of mice and men. Int Rev Immunol. 2006;25:321–352. doi:10.1080/08830180600992498.
   PubMed Web of Science ®Google Scholar
• Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E. Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. 1990; 50: 7820–7825. http://aacrjournals.org/cancerres/article-pdf/50/24/7820/2442042/cr0500247820.pdf.
   Google Scholar
• Omori R, Eguchi J, Hiroishi K, Ishii S, Hiraide A, Sakaki M, Doi H, Kajiwara A, Ito T, Kogo M, et al. Effects of interferon-α-transduced tumor cell vaccines and blockade of programmed cell death-1 on the growth of established tumors. Cancer Gene Ther. 2012;19:637–643. doi:10.1038/cgt.2012.42.
   PubMed Web of Science ®Google Scholar
• Castaldello A, Sgarbanti M, Marsili G, Brocca-Cofano E, Remoli AL, Caputo A, Battistini A. Interferon regulatory factor-1 acts as a powerful adjuvant in tat DNA based vaccination. J Cell Physiol. 2010;224:702–709. doi:10.1002/jcp.22169.
   PubMed Web of Science ®Google Scholar
• Kepp O, Tartour E, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology. 2014;3:e955691. doi:10.4161/21624011.2014.955691.
   PubMed Web of Science ®Google Scholar
• Golden EB, Apetoh L. Radiotherapy and immunogenic cell death. Semin Radiat Oncol. 2015;25:11–17. doi:10.1016/j.semradonc.2014.07.005.
   PubMed Web of Science ®Google Scholar
• Perez CA, Fu A, Onishko H, Hallahan DE, Geng L. Radiation induces an antitumour immune response to mouse melanoma. Int J Radiat Biol. 2009;85:1126–1136. doi:10.3109/09553000903242099.
   PubMed Web of Science ®Google Scholar
• Muragaki Y, Maruyama T, Iseki H, Tanaka M, Shinohara C, Takakura K, Tsuboi K, Yamamoto T, Matsumura A, Matsutani M, et al. Phase I/IIa trial of autologous formalin-fixed tumor vaccine concomitant with fractionated radiotherapy for newly diagnosed glioblastoma - Clinical article. J Neurosurg. 2011;115:248–255. doi:10.3171/2011.4.JNS10377.
   PubMed Web of Science ®Google Scholar
• McDonald JU, Kaforou M, Clare S, Hale C, Ivanova M, Huntley D, Dorner M, Wright VJ, Levin M, Martinon-Torres F, et al. A simple screening approach to prioritize genes for functional analysis identifies a role for interferon regulatory factor 7 in the control of respiratory syncytial virus disease. mSystems. 2016 1: 10.1128/msystems.00051-16.
   Web of Science ®Google Scholar
• Coit P, Ortiz-Fernandez L, Lewis EE, McCune WJ, Maksimowicz-McKinnon K, Sawalha AH. A longitudinal and transancestral analysis of DNA methylation patterns and disease activity in lupus patients. JCI Insight. 2020 5; 5: 10.1172/jci.insight.143654.
   PubMed Web of Science ®Google Scholar
• Bogunovic D, Byun M, Durfee LA, Abhyankar A, Sanal O, Mansouri D, Salem S, Radovanovic I, Grant AV, Adimi P, et al. Mycobacterial disease and impaired IFN-γ immunity in humans with inherited ISG15 deficiency. Science (1979). 2012;337:1684–1688. doi:10.1126/science.1224026.
   PubMed Web of Science ®Google Scholar
• Bidwell BN, Slaney CY, Withana NP, Forster S, Cao Y, Loi S, Andrews D, Mikeska T, Mangan NE, Samarajiwa SA, et al. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med. 2012;18:1224–1231. doi:10.1038/nm.2830.
   PubMed Web of Science ®Google Scholar
• Ning S, Pagano JS, Barber GN. IRF7: activation, regulation, modification and function. Genes Immun. 2011;12:399–414. doi:10.1038/gene.2011.21.
   PubMed Web of Science ®Google Scholar
• Aldridge DL, Phan AT, de Waal Malefyt R, Hunter CA. Limited Impact of the inhibitory receptor TIGIT on NK and T cell responses during toxoplasma gondii infection. Immunohorizons. 2021;5:384–394. doi:10.4049/immunohorizons.2100007.
   PubMedGoogle Scholar
• Abdel-Wahab Z, Dar MM, Hester D, Vervaert C, Gangavalli R, Barber J, Darrow TL, Seigler HF. Effect of irradiation on cytokine production, MHC antigen expression, and vaccine potential of interleukin-2 and interferon-gamma gene-modified melanoma cells. 1996;171:246–254. doi:10.1006/cimm.1996.0200.
   Google Scholar
• Abdel-Wahab Z, Weltz C, Hester D, Pickett N, Vervaert C, Barber JR, Jolly D, Seigler HF. A phase I clinical trial of immunotherapy with interferon-γ gene-modified autologous melanoma cells: monitoring the humoral immune response. Cancer. 1997;80:401–412. doi:10.1002/(SICI)1097-0142(19970801)80:3<401:AID-CNCR8>3.0.CO;2-U.
   PubMed Web of Science ®Google Scholar
• Jackson SW, Jacobs HM, Arkatkar T, Dam EM, Scharping NE, Kolhatkar NS, Hou B, Buckner JH, Rawlings DJ. B cell IFN-γ receptor signaling promotes autoimmune germinal centers via cell-intrinsic induction of BCL-6. J Exp Med. 2016;213:733–750. doi:10.1084/jem.20151724.
   PubMed Web of Science ®Google Scholar
• Harris DP, Goodrich S, Gerth AJ, Peng SL, Lund FE. Regulation of IFN-γ production by B effector 1 cells: essential roles for T-bet and the IFN-γ receptor. J Immunol. 2005;174:6781–6790. doi:10.4049/jimmunol.174.11.6781.
   PubMed Web of Science ®Google Scholar
• Guo FF, Cui JW. The role of tumor-infiltrating B cells in tumor immunity. J Oncol. 2019;2019:1–9. doi:10.1155/2019/2592419.
   Web of Science ®Google Scholar
• Van Herpen CML, Van Der Voort R, JAWM VDL, Klasen IS, De GA, Van Kempen LCL, De Vries IJM, Duiveman-De BT, Dolstra H, Torensma R, et al. Intratumoral rhIL-12 administration in head and neck squamous cell carcinoma patients induces B cell activation. Int J Cancer. 2008;123:2354–2361. doi:10.1002/ijc.23756.
   PubMed Web of Science ®Google Scholar